Optimization of a Protein-Targeted Medicine into an RNA-Specific Small Molecule

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• Small molecule drugs often bind to RNA, influencing cellular processes.
• RNA is increasingly recognized as a critical on- and off-target for therapeutics.
• Kinase inhibitors, like dovitinib, are known to bind RNA and affect microRNA biogenesis.

Purpose of the Study:

• To design novel small molecules that specifically inhibit RNA targets.
• To minimize off-target activity against canonical protein targets.
• To leverage molecular recognition principles for RNA-targeted drug design.

Main Methods:

• Utilized dovitinib's known binding interactions with both protein and RNA.
• Employed structure-based design principles to create RNA-specific inhibitors.
• Assessed compound activity against both RNA and protein targets in cellular models.

Main Results:

• Successfully designed molecules with specific RNA inhibitory activity.
• Achieved lack of activity against intended protein targets.
• Demonstrated the feasibility of targeting RNA while avoiding protein interactions.

Conclusions:

• RNA should be considered a significant target and off-target in small molecule drug development.
• Design principles can be applied to create selective RNA-targeted therapeutics.
• This approach offers a strategy to enhance drug efficacy and safety by minimizing off-target effects.